Drug Development Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X

Impel doses first subject in Phase l trial of INP105

Image showing brain areas more active in controls than in schizophrenia patients during a working memory task for a fMRI study. Credit: Kim J, Matthews NL, Park S.



Go Top